Health
FDA Declines to Approve Summit's Lung Cancer Drug as the Survival Gain Falls Short
The refusal closes this drug's fastest U.S. route and sets the survival bar for a whole class of two-target cancer drugs now in rival pipelines.
The Food and Drug Administration declined to approve Summit's ivonescimab with chemotherapy, saying the trial did not show that patients lived longer.
Summit Therapeutics announced on Sunday, November 15, that the Food and Drug Administration (FDA) had issued the letter. A complete response letter is a formal notice that an application cannot be approved as filed.
The application covered ivonescimab combined with platinum-containing chemotherapy for a common form of lung cancer. The patients had locally advanced or metastatic non-small cell lung cancer (NSCLC) after treatment with a third-generation EGFR TKI, a targeted cancer drug.
The FDA's target decision date, its PDUFA date, was Saturday, November 14, 2026. Cancer Network reported the agency had accepted the application in January 2026 and assigned that date.
What the FDA required
According to Summit, the FDA said the application cannot be approved in its present form. The agency found substantial evidence of effectiveness is not established without a statistically significant overall survival improvement.
Overall survival, whether patients lived longer, was the missing piece. Summit said the progression-free survival benefit, without a significant survival benefit, does not support a positive benefit-risk profile.
Summit noted that no FDA-approved regimen has shown a statistically significant survival benefit in this patient setting. The primary survival analysis showed a positive trend, the company said, but it was not statistically significant.
In a post-hoc analysis, longer-term follow-up of Western patients showed a hazard ratio of 0.76. Post-hoc means the analysis was designed after the trial data were seen, so it carries less weight.
Summit reported the post-hoc hazard ratio of 0.76 in the full population, the Asian patients and the Western patients. The company presented that consistency as support, but the post-hoc result did not change the FDA's test.
The HARMONi numbers
The application rested on HARMONi, a global, randomized, double-blind Phase III trial. It compared ivonescimab plus platinum chemotherapy with placebo plus the same chemotherapy in 438 patients, 219 per arm.
Every patient had EGFR-mutated, locally advanced or metastatic non-squamous NSCLC. Each had already been treated with a third-generation EGFR TKI, and the trial had two primary endpoints: progression-free survival and overall survival.
HARMONi met its progression-free survival endpoint. Median progression-free survival was 6.8 months on ivonescimab against 4.4 months on placebo, a hazard ratio of 0.52 (95% CI 0.41-0.66; P <.0001).
Summit called HARMONi the first global Phase III immunotherapy-based study to show a significant progression-free gain here. Delaying progression, however, was not the endpoint the FDA ultimately required for approval.
The primary overall survival analysis, in April 2025, showed median survival of 16.8 months against 14.0 months. The hazard ratio was 0.79 (95% CI 0.62-1.01; P = .057), which is not statistically significant.
A later analysis in September 2025 showed a hazard ratio of 0.78 (95% CI 0.62-0.98; P = .0332). A June 2026 data cutoff showed 0.76 for the full population and the Western subgroup, the post-hoc figure Summit cites.
What markets made of it
Summit shares fell 19.9% to $11.33 in premarket trading on Monday, Reuters reported. That move came before the bell, while the regular session was still ahead, and it is not a closing price.
Akeso, the drug's inventor in China, fell harder in Hong Kong. Its shares dropped 22.11% for the day, closing at HK$64.10, Longbridge reported in its Monday close wrap.
The two moves are different vintages of the same verdict. Summit's was a premarket reaction in New York, while Akeso's was a settled Hong Kong close.
Why it matters beyond Summit
BMO Capital analyst Evan Seigerman said the decision establishes a meaningful regulatory precedent for the drug class. Reuters reported he saw potential implications for similar candidates at Bristol-Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.
The precedent is about evidence, not about one company's trial conduct. A progression benefit alone, without patients living significantly longer, now has a documented refusal behind it in this setting.
TD Cowen took the other side of the trade. Its analysts said the decision matched the high bar the agency had previously set, Reuters reported.
TD Cowen said the rejection does not affect the probability of success in first-line NSCLC. It called first-line use the substantially larger and more important commercial opportunity, and analysts are watching first-line data expected later this year.
The drug, the license and safety
Ivonescimab is a bispecific antibody, one molecule that blocks two targets. It blocks PD-1, which helps cancer evade the immune system, and VEGF, which tumors use to grow blood vessels.
Akeso invented the drug, known as SMT112 in Summit's territories and AK112 elsewhere. It was first approved in China in May 2024, and no PD-1 x VEGF bispecific antibody is approved in the United States.
Summit acquired rights in the United States, Canada, Europe and Japan from Akeso in 2022. Reuters reported the deal was valued at up to $5 billion, with Akeso retaining China and other markets.
More than 5,000 patients have been treated with ivonescimab in trials globally, Summit said. The company is based in Miami, Florida, and trades on Nasdaq as SMMT.
Safety did not drive the refusal, on Summit's account. The company called the profile acceptable and manageable, with no new safety signals in HARMONi.
Sixteen patients, 7.3%, stopped ivonescimab over treatment-related adverse events, against 11 patients, 5.0%, on placebo. Deaths from treatment-related adverse events were four patients, 1.8%, on ivonescimab against five, 2.3%, on placebo.
Summit's chairman and co-chief executive, Robert W. Duggan, said the company was disappointed for patients and families. His verbatim words were: "We are disappointed for patients and their families awaiting additional treatment options in this setting."
He added that five positive Phase III studies between Summit and Akeso leave the company's belief unchanged. The company said its determination to advance ivonescimab's development is also unchanged.
The wider program continues in earlier lines of treatment. HARMONi-3 tests the drug in first-line metastatic NSCLC, HARMONi-7 in first-line disease with high PD-L1, and HARMONi-GI3 in colorectal cancer.
What remains unknown
What remains unknown: Summit did not say whether it will request a meeting, resubmit, appeal or run a new trial. The release states no next regulatory step, so the path back to the FDA is unstated.
Summit reported no manufacturing or inspection reason for the letter. The complete response letter itself is not public, so its full contents cannot be verified beyond Summit's account, which Reuters corroborated on the outcome.
It is also unknown whether the FDA would accept longer follow-up of HARMONi as sufficient. The alternative, a new trial powered for overall survival, would take years rather than months.
Whether the first-line program clears the survival bar is equally open. HARMONi-3 is a different population and a different test, and its data have not yet been reported.
The tests that come next
What to watch: Summit's first stated next step with the FDA. A meeting request, a resubmission plan or a new-trial announcement would each reset the timeline for this indication.
Watch the first-line data expected later this year, which TD Cowen's analysts flagged. A survival-positive first-line result would reframe this refusal as one setting's bar, not the drug's ceiling.
Watch rival PD-1 x VEGF programs for changed trial designs. Longer survival follow-up or survival-powered endpoints at Bristol-Myers Squibb, BioNTech, Pfizer, Merck or AbbVie would show the precedent binding in practice.
Sources & evidence
Source checked4 sources · 13 figures
Figure receipts
Sources
Sources used for this piece.
Cancer Network
Summit Therapeutics
Reuters
Reuters - Summit shares drop after US FDA declines to approve lung cancer drug, Nov. 16, 2026
Longbridge
Longbridge - Hong Kong close wrap with Akeso (09926) down 22.11%, Nov. 16, 2026
As of Monday, Nov. 16, 2026.

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

